I would like to add a note on innovation and patent protection. What we're seeing more and more is the patenting of what are called isomers of existing molecules. The molecule has two orientations in space. The patent is due to expire and a new drug, which is one of the orientations in space of the same molecule, but with a very different brand name, is then produced by the same company. So it's really an evergreening of the patent.
Nexium is the cause célèbre of that. It's a lot like Lastium, but it's one of the leading drugs in terms of spending. So you have to ask--going back to how we are treating patients--whether this is actually meeting the needs of as many patients as possible for a specific sum of money.